Analytical Data
-
Gene name
GAGE12F
- Application
-
Alternative Names
GAGE12F;G antigen 12F
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P0CL80
-
Expression Region
1-117aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSMSWRGRS TYYWPRPRRY VQPPEMIGPM RPEQFSDEVE PATPEEGEPA TQRQDPAAAQ EGEDEGASAG QGPKPEAHSQ EQGHPQTGCE CEDGPDGQEM DPPNPEEVKT PEEGEKQSQC
-
Molecular Weight
15 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GAGE12F is a member of the GAGE (G antigen) family, which is known for its potential role in cancer immunotherapy due to its expression in various malignancies but not in normal tissues, making it a promising target for tumor-specific immune responses. The background of research on GAGE12F centers on its use as a cancer/testis (CT) antigen, a classification of antigens that elicit immune responses in cancer patients while remaining largely unexpressed in healthy adult tissues, thus minimizing potential autoimmune reactions. Initial studies have indicated that GAGE12F may be involved in tumor progression and could serve as a biomarker for certain cancers, including melanoma and other solid tumors. Researchers are investigating the molecular mechanisms underlying its expression and function, hoping to develop peptide-based vaccines or adoptive T-cell therapies that can enhance tumor-specific immunity. This interest is fueled by the growing understanding of the immune system's role in targeting cancer cells, and the need for innovative therapeutic strategies. Additionally, GAGE12F's immunogenic properties are being explored in combination with other therapeutic modalities to improve clinical outcomes for patients suffering from cancer. Thus, the ongoing study of GAGE12F and its potential applications in cancer treatment holds significant promise for advancing personalized medicine and enhancing the efficacy of immunotherapeutic approaches.
